Trial Design: Open-label, multicentre phase Ib/IIa study of AZD2014 (vistusertib) administered with selumetinib. There are two parts to this study: a dose-escalation part in treatment-refractory advanced solid tumours and a subsequent separate expansion cohort part for TNBC, squamous cell lung cancers, non-squamous cell lung cancers with KRAS mutations and non-squamous cell lung cancers with wild-type KRAS. The study will also assess the relationship between the anticipated anti-tumour activity of the treatment regimen and biological characteristics of patients’ tumour at baseline.
A study of vistusertib in combination with selumetinib in patients with advanced cancers: TORCMEK phase Ib results. Peter Schmid, Martin David Forster, Yvonne J. Summers et al. Journal of Clinical Oncology (2017) 35:15_suppl, 2548-2548
Cancer Research UK website A trial looking at AZD2014 and selumetinib for advanced cancer (TORCMEK)